Of greatest interest is also that tumours with oncogenic driver mutations are largely free of processing mutations, which might be helpful to aid therapy decisions in favour of immunotherapy, regardless of PD-L1 expression, as long as no targeted therapy is indicated. This evidence concerns the gene CD274 and neoplasm.